Marie Jarosova

11PUBLICATIONS
30CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Veterinary pharmacologyGene expression (incl. microarray and other genome-wide approaches)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jan 08, 2025
Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study.

Elizabeth H Phillips, Nicholas Counsell, Tim Illidge

|Nov 07, 2024
Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: A British Society for Haematology Good Practice Paper.

Aisling Barrett, Nimish Shah, Andrew Chadwick

|Dec 21, 2022
Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials.

Valeria Fiaccadori, Anouk Neven, Catherine Fortpied

|Jul 18, 2022
Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trial.

Elizabeth H Phillips, Catherine Burton, Amy A Kirkwood

|Apr 29, 2022
A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.

Andrea Kuhnl, Claire Roddie, Amy A Kirkwood

|Oct 12, 2021
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.

Wei Yee Chan, Nicholas Counsell, Ruth de Tute

Pageof 2

Frequent Collaborators

2 joint publications

Pamela McKay

2 joint publications

Tim M Illidge

2 joint publications

Ruth de Tute

2 joint publications

Dunnya De-Silva